Aptose Biosciences (TSE:APS) Shares Cross Above 50 Day Moving Average – Time to Sell?

Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of C$2.31 and traded as high as C$2.38. Aptose Biosciences shares last traded at C$2.26, with a volume of 17,424 shares trading hands.

Aptose Biosciences Trading Down 3.0%

The company has a market capitalization of C$5.77 million, a PE ratio of -0.22 and a beta of -1.24. The company’s fifty day moving average is C$2.31 and its 200-day moving average is C$2.23. The company has a debt-to-equity ratio of -98.74, a current ratio of 0.55 and a quick ratio of 5.41.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported C($4.16) earnings per share (EPS) for the quarter. On average, analysts anticipate that Aptose Biosciences Inc. will post -0.59 EPS for the current fiscal year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.